Hugel posted its highest-ever quarterly earnings in the second quarter of 2025, driven by strong global demand for its botulinum toxin and hyaluronic acid (HA) filler products.
The South Korea-based medical aesthetics company posted KRW 110.3 billion (approx. USD 79.33 million) in net sales and KRW 56.7 billion (approx. USD 40.78 million) in operating profit for the April–June period, marking year-on-year increases of 15.5% and 33.6%, respectively. Net income for the quarter came in at KRW 38.2 billion (approx. USD 27.48 million), up 3.3% from the previous year.
The company’s cumulative sales for the first half of the year reached KRW 200 billion (approx. USD 143.87 million), continuing the momentum from the second half of 2024. First-half operating profit stood at KRW 95.6 billion (approx. USD 68.76 million).
The company attributed the strong performance to robust overseas demand for its core products. Exports of botulinum toxin and HA fillers rose 21% year-on-year to KRW 69.8 billion (approx. USD 50.20 million) in Q2, accounting for 63% of the company’s total sales. Hugel is the first and only Korean firm to have secured regulatory approvals for botulinum toxin products in the United States, China, and Europe — the world’s three largest toxin markets.
By product, botulinum toxin, domestically named Botulax and globally branded as Letybo, hit KRW 61.2 billion (approx. USD 44.06 million) in net sales for the second quarter with a 20% on-year increase and exceeded KRW 100 billion (approx. USD 71.93 million) in cumulative sales for the first half. The sales were backed by the additional shipments to the US in June, following the official launch in the country in March, and the steady growth in the Asia-Pacific markets such as China, Taiwan, and Australia.
The net sales of hyaluronic acid filler, locally branded as THE CHAEUM and BYRYZN Skin Booster HA, reached KRW 34.1 billion (approx. USD 24.53 million) for the second quarter with solid growth in the APAC and European markets. The cosmetics brands, such as WELLAGE and BYRYZN BR, showed a 104.5% increase on-year to KRW 13.6 billion (approx. USD 9.78 million) in the same period.
“We achieved record quarterly net sales and operating profit with strong performances from our core products and new growth segments,” a Hugel official said. “In the second half, we plan to deepen our U.S. market penetration and further strengthen our presence in China and other emerging markets, including the Middle East.”
